ANT2 suppression by shRNA may be able to exert anticancer effects in HCC further by restoring SOCS1 expression

Area of Science:

• Oncology
• Molecular Biology
• Epigenetics

Background:

• Suppressor of cytokine signaling 1 (SOCS1) negatively regulates the Jak-STAT pathway.
• SOCS1 is epigenetically silenced via promoter methylation in hepatocellular carcinoma (HCC).
• Restoring SOCS1 expression is a potential therapeutic strategy for HCC.

Purpose of the Study:

• To investigate the effect of adenine nucleotide translocase 2 (ANT2) suppression on SOCS1 expression in HCC.
• To elucidate the downstream mechanisms by which ANT2 suppression impacts HCC progression.

Main Methods:

• Short-hairpin RNA (shRNA) mediated knockdown of ANT2 in Hep3B HCC cells.
• Analysis of SOCS1 expression, promoter methylation, and DNA methyltransferase 1 (DNMT1) activity.
• Assessment of Ras/PI3K/Akt signaling pathway, STAT3 activity, and miR-21 expression.
• Evaluation of Hep3B cell proliferation in vitro.

Main Results:

• ANT2 suppression by shRNA restored SOCS1 expression and demethylated its promoter in Hep3B cells.
• ANT2 knockdown decreased DNMT1 activity via suppression of the Ras/PI3K/Akt pathway.
• Restored SOCS1 inhibited STAT3 activity and downregulated onco-miR-21.
• miR-21 downregulation significantly suppressed HCC cell proliferation.

Conclusions:

• ANT2 suppression can restore SOCS1 expression and exert anticancer effects in HCC.
• The mechanism involves epigenetic modification, pathway inhibition, and downregulation of onco-miR-21.
• Targeting ANT2 represents a promising therapeutic approach for hepatocellular carcinoma.